Supplementary Figure 4 from Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type &lt;i&gt;KRAS&lt;/i&gt; Metastatic Colorectal Cancer